Gilead Sciences, Inc. — GILD

Close PriceMarket CapP/E RatioForward P/E RatioImplied Growth*Implied Forward Growth*DividendP/B Ratio
$134.43$166.90B18.314.010.7%7.9%$3.28
2.4%		7.1

Latest Headlines

Revenue & Net Income

Revenue & Net Income
Date Revenue Net_Income EPS Last_Updated Revenue_Change Net_Income_Change EPS_Change
0 2020-12-31 $24,689M $123M $0.10 2024-02-09 04:07:05 N/A N/A N/A
1 2021-12-31 $27,281M $4,592M $4.96 2026-03-10 08:36:05 10.5% 3633.3% 4860.0%
2 2022-12-31 $27,281M $4,592M $3.66 2026-05-29 09:08:23 0.0% 0.0% -26.2%
3 2023-12-31 $27,116M $5,665M $4.54 2026-05-29 09:08:23 -0.6% 23.4% 24.0%
4 2024-12-31 $28,754M $480M $0.38 2026-05-29 09:08:23 6.0% -91.5% -91.6%
5 2025-12-31 $29,442M $8,510M $6.84 2026-05-29 09:08:23 2.4% 1672.9% 1700.0%
6 TTM 2026-03-31 $29,734M $9,216M $7.36 2026-05-19 09:07:39 1.0% 8.3% 7.6%

EPS

EPS

Forecasts

Revenue/Net Income Forecast EPS Forecast

Y/Y % Change

Revenue YoY Change EPS YoY Change
YoY Growth Rates

GILD Year-over-Year Growth

  2020 2021 2022 2023 2024 2025 2026 2027 Average
Revenue Growth (%) 10.5% 0.0% -0.6% 6.0% 2.4% 3.4% 6.2% 4.0%
Revenue Analysts (#) 0 0 0 0 0 0 24 24
EPS Growth (%) 3633.3% 0.0% 23.4% -91.5% 1672.9% -111.6% -1305.8% 545.8%
EPS Analysts (#) 0 0 0 0 0 0 25 25

Forward Estimate History

How the next-FY EPS and revenue estimates have drifted over time. One line per fiscal year – past lines end when that FY became current.

Forward EPS projection history by FY Forward revenue projection history by FY

Expenses

Revenue vs Expenses
Year Revenue ($) Cost of Revenue ($) R&D ($) Sales & Marketing ($) G&A ($) SG&A ($) Facilities / D&A ($)
2022 $27.3B $3.6B $5.0B $0.0 $0.0 $5.7B $2.1B
2023 $27.1B $3.8B $5.7B $3.3B $2.8B $6.1B $2.7B
2024 $28.8B $3.5B $5.9B $3.5B $2.5B $6.0B $2.8B
2025 $29.4B $3.5B $5.8B $3.5B $2.2B $5.7B $2.8B
TTM $29.7B $3.4B $5.8B $3.7B $2.2B $5.9B $2.8B
Expenses % of Revenue
Year Revenue Change (%) Cost of Revenue Change (%) R&D Change (%) Sales & Marketing Change (%) G&A Change (%) SG&A Change (%) Facilities / D&A Change (%)
2023 -0.60 7.06 14.89 inf inf 6.86 28.06
2024 6.04 -8.44 3.31 5.53 -8.71 -1.02 2.75
2025 2.39 -0.29 -1.83 2.00 -14.17 -4.87 -0.25
TTM 0.99 -2.53 -0.10 4.12 2.20 3.38 -0.25
No unmapped expenses.

Segment Performance

axis1_GILD_Product.png axis1_GILD_H_I_V_Product_Sales.png axis1_GILD_H_I_V_Products_Biktarvy.png axis1_GILD_Oncology_Product.png axis1_GILD_Liver_Disease.png axis1_GILD_H_I_V_Products_Descovy.png axis1_GILD_Cell_Therapy_Products_Total_Cell_Therapy_Product_Sales.png axis1_GILD_H_I_V_Products_Genvoya.png axis1_GILD_Other_Products_Yescarta.png axis1_GILD_Liver_Disease_Products_Sofosbuvir_Velpatasvir.png axis1_GILD_Trodelvy.png axis1_GILD_Veklury.png axis1_GILD_H_I_V_Products_Odefsey.png axis1_GILD_Liver_Disease_Products_Vemlidy.png axis1_GILD_Other_Products_Total_Other_Product_Sales.png axis1_GILD_Liver_Disease_Products_Other_Liver_Disease.png axis1_GILD_H_I_V_Products_Symtuza_Revenue_Share.png axis1_GILD_Other_Products_Am_Bisome.png axis1_GILD_Royalty_Contract_And_Other.png axis1_GILD_H_I_V_Products_Other_H_I_V.png axis1_GILD_Cell_Therapy_Products_Tecartus.png axis1_GILD_Other_Products_Other.png
SEGMENTS v2025-09-09 · 2026-05-29 09:08 UTC — Units: $B. Rows list fiscal years (last 3 + TTM) with revenue for each segment; the final row shows the TTM revenue mix (operating income columns display “—” where mix is not applicable).
Year Prod Rev H I V Product Sales Rev H I V Products Biktarvy Rev Oncology Product Rev Liver Disease Rev H I V Products Descovy Rev Cell Therapy Products Total Cell Therapy Product Sales Rev H I V Products Genvoya Rev Other Products Yescarta Rev Liver Disease Products Sofosbuvir Velpatasvir Rev Trodelvy Rev Veklury Rev H I V Products Odefsey Rev Liver Disease Products Vemlidy Rev Other Products Total Other Product Sales Rev Liver Disease Products Other Liver Disease Rev H I V Products Symtuza Revenue Share Rev Other Products Am Bisome Rev Royalty Contract And Other Rev H I V Products Other H I V Rev Cell Therapy Products Tecartus Rev Other Products Other Rev Total Rev
2023 80.8B 36.4B 23.7B 5.86B 5.57B 3.97B 3.74B 4.12B 3.00B 3.07B 2.12B 4.37B 2.70B 1.72B 1.72B 0.77B 1.06B 0.98B 0.55B 0.80B 0.74B 0.73B 188.5B
2024 85.8B 39.2B 26.8B 6.58B 6.04B 4.22B 3.95B 3.52B 3.14B 3.19B 2.63B 3.60B 2.58B 1.92B 1.78B 0.93B 1.18B 1.06B 0.43B 0.87B 0.81B 0.71B 201.1B
2025 86.7B 41.5B 28.7B 6.47B 6.43B 5.51B 3.68B 3.00B 2.99B 2.54B 2.79B 1.82B 2.33B 2.14B 1.60B 1.75B 0.99B 1.02B 1.58B 1.00B 0.69B 0.58B 205.8B
TTM 213.3B 100B 68.5B 16.2B 15.5B 12.5B 9.37B 7.78B 7.57B 6.99B 6.81B 6.31B 5.92B 5.03B 4.19B 3.15B 2.68B 2.63B 2.22B 2.20B 1.80B 1.55B 502.2B
% of Total (TTM) 42.5% 19.9% 13.6% 3.2% 3.1% 2.5% 1.9% 1.5% 1.5% 1.4% 1.4% 1.3% 1.2% 1.0% 0.8% 0.6% 0.5% 0.5% 0.4% 0.4% 0.4% 0.3% 100%

Balance Sheet

Balance Sheet
  Metric Value
0 Total Assets $56,278M
1 Cash $7,628M
2 Total Liabilities $32,847M
3 Total Debt $22,174M
4 Total Equity $23,515M
5 Debt to Equity Ratio 0.94

EPS & Dividend

EPS & Dividend

Valuation

Valuation
Share Price Treasury Yield Estimates Fair Value (P/E) Fair Value (P/S) Current P/S Current P/E
$134.43 4.5% Nicks Growth: 2%
Nick's Expected Margin: 15%
FINVIZ Growth: 9%		 Nicks: 8
Finviz: 16		 Nick's: 1.170 5.6 18.3
Basis Year Nicks Valuation Nicks vs Share Price Finviz Valuation Finviz vs Share Price
$7.36 EPS TTM $57.41 -57.3% $114.59 -14.8%
$24.53 Revenue 2026 $28.70 -78.6% $57.29 -57.4%
$9.59 EPS 2027 $74.77 -44.4% $149.24 11.0%

Implied Growth

Implied Growth
Average Median Std Dev Current Percentile
TTM Forward TTM Forward TTM Forward TTM Forward TTM Forward
Timeframe
1 Year 12.02% 8.44% 12.18% 8.44% 0.99% 0.59% 10.80% 8.03% 18.3% 25.8%
3 Years 12.02% 8.44% 12.18% 8.44% 0.99% 0.59% 10.80% 8.03% 18.3% 25.8%
5 Years 12.02% 8.44% 12.18% 8.44% 0.99% 0.59% 10.80% 8.03% 18.3% 25.8%
10 Years 12.02% 8.44% 12.18% 8.44% 0.99% 0.59% 10.80% 8.03% 18.3% 25.8%

← Back